Halozyme Therapeutics (HALO) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- $2.28
- Estimate
- $1.82
- Surprise
- +25.5%
- Revenue (period 2026-06-30)
- $481.0M
- Score at report (before → after)
- 6.7 → 6.7/10
Revenue source: xbrl.
How the report landed
Halozyme Therapeutics (HALO) beat the $1.82 estimate with adjusted EPS of $2.28 — a large 25.5% upside surprise. TrendMatrix's engine moved from Sell (6.7/10) to Buy (Wait) at 6.7/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates HALO Buy (Wait) at 6.4/10.
3 of the last 4 quarters beat the estimate; this quarter's +25.5% surprise compares with a -18.7% four-quarter average. Next scheduled report: 2026-11-02.
What supports the rating
- V7 flight-to-quality bonus: +0.5 (Q=9.1 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Analyst target reached - limited upside remaining
- Near 52-week high (4.0% away)
- Leverage penalty (D/E 15.2): -1.5
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $112.12
- Entry target
- $107.14
- Price target
- $114.50
- Stop
- $102.33
- Upside to target
- +2.1%
The stock trades at 32.1× trailing but 10.6× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-10-07 — shown for context, not personalized investment advice.
HALO at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $12.45B
- P/E (fwd)
- 10.6
- P/E (ttm)
- 32.1
- 52-week range
- $61.23–$116.85
- Off 52-week high
- 4.0%
- RSI (14)
- 54
- Volume vs avg
- 0.21×
- Score today
- 6.4/10